NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNERCID is an injectable streptogramin antibiotic combination (quinupristin/dalfopristin) approved in 1999 for treating serious infections caused by gram-positive bacteria. It is administered intravenously and represents a unique dual-component mechanism targeting bacterial protein synthesis. The drug is primarily used for resistant gram-positive infections where alternative agents may be limited.
LOE Approaching
With LOE approaching and limited direct pipeline expansion, career roles on SYNERCID likely focus on managing market erosion and optimizing hospital formulary position rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
Started Jun 2000
Gram-Positive Bacterial Infections
Career Relevance
SYNERCID offers limited career growth opportunities given its LOE-approaching status and zero linked job postings; roles emphasize preserving market share in hospital settings and managing transition to post-patent competition. Professionals seeking growth, innovation, or career trajectory expansion should consider this a niche or transitional assignment rather than a flagship opportunity.
Hospital Account Manager
Worked on SYNERCID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.